GLP-1 for HIV Patients: ART-Related Weight Gain on Integrase Inhibitors

Modern antiretroviral therapy (ART) has turned HIV into a chronic, manageable condition with near-normal life expectancy for adherent patients — but the integrase strand transfer inhibitors (INSTIs) that anchor most first-line regimens carry a well-documented weight-gain signal. Dolutegravir (Tivicay, Dovato), bictegravir (in Biktarvy), and cabotegravir (Vocabria, Cabenuva) are associated with 5–15 kg of weight gain over 12–24 months, with the largest gain in patients who also switch from older NRTIs to tenofovir alafenamide (TAF). The published cohorts of GLP-1 receptor agonists in people with HIV (Nguyen 2024^[6], Haidar 2024^[7]) show clinically meaningful weight loss without compromising virologic suppression. There is no documented pharmacokinetic interaction between INSTIs and GLP-1 receptor agonists. This article walks through the ART pharmacology, the GLP-1 evidence in HIV, and the practical ID-plus-obesity-medicine consult pathway.

The honest summary

• INSTI-associated weight gain is real. In the NA-ACCORD cohort (Bourgi 2020^[1]), treatment-naive adults starting INSTI-based regimens gained significantly more weight than those starting NNRTIs or PIs — the adjusted mean difference was 2–3 kg in the first two years, with the largest sub-group gains in Black women on dolutegravir plus TAF. Pooled randomized-trial analysis (Sax 2020^[3]) confirmed the signal.
• Mechanism is not well understood. The McComsey review (Eckard 2020^[4]) walks through the leading hypotheses — reversal of the catabolic drive of untreated HIV (“return-to-health”), a possible direct INSTI effect on adipocyte differentiation, and removal of the appetite-suppressing effect of older NRTIs (zidovudine, efavirenz). No single mechanism has been confirmed.
• GLP-1 receptor agonists work in HIV. Nguyen 2024^[6] (retrospective cohort of 222 patients with HIV on GLP-1 RAs) found mean weight loss of 6.5% at 12 months with semaglutide and 10.3% with tirzepatide, with no loss of virologic suppression. Haidar 2024^[7] (CNICS cohort, n=222) reported −6.1 kg on semaglutide at 12 months in people with HIV.
• No INSTI-GLP-1 drug interaction. Dolutegravir, bictegravir, raltegravir, and cabotegravir are metabolized primarily by UGT1A1 with minor CYP3A4 contribution; GLP-1 receptor agonists do not meaningfully alter UGT or CYP activity. Continue full-dose ART, add the GLP-1 with standard titration, monitor viral load on the usual schedule.

HIV epidemiology and the modern ART landscape

Roughly 1.2 million US adults are living with HIV. The standard of care is lifelong combination ART, almost always anchored on an INSTI: dolutegravir (Tivicay, also in Dovato and Triumeq), bictegravir (only available in the single-tablet regimen Biktarvy), or cabotegravir (the long-acting injectable Cabenuva, given with rilpivirine every one or two months). Backbone NRTIs are either tenofovir alafenamide (TAF, Descovy/Vemlidy) plus emtricitabine, or abacavir plus lamivudine (in Triumeq). Older NNRTIs (efavirenz, rilpivirine, doravirine) and protease inhibitors (darunavir, atazanavir, usually boosted with ritonavir or cobicistat) are now mostly reserved for switch therapy or resistance-driven regimens.

What the INSTI weight-gain data actually shows

The signal first emerged from the ADVANCE and NAMSAL first-line trials. NAMSAL (NEJM 2019^[2]) randomized 613 treatment-naive adults in Cameroon to dolutegravir or low-dose efavirenz, both with tenofovir disoproxil fumarate plus lamivudine; mean weight gain at 48 weeks was 5.0 kg on dolutegravir vs 3.0 kg on efavirenz, with obesity (BMI ≥ 30) incidence 12% vs 5%. ADVANCE compared dolutegravir plus TAF vs dolutegravir plus TDF vs efavirenz plus TDF and found the TAF-plus-dolutegravir arm gained the most — about 6 kg at 48 weeks and 8–10 kg by 96 weeks.

Bourgi 2020^[1] extended the signal to a North American observational cohort of 22,972 treatment-naive adults. Two-year weight gain was 4.9 kg on INSTI-based regimens vs 3.3 kg on NNRTI and 3.7 kg on PI; the INSTI-specific gain was greatest with dolutegravir (5.9 kg). The Sax 2020 pooled randomized-trial analysis^[3] reached the same conclusion: female sex, Black race, low baseline CD4, high baseline viral load, INSTI anchor, and TAF backbone were all independent risk factors for clinically significant weight gain.

The mechanism remains unsettled (Eckard 2020^[4]). The leading candidates are (1) reversal of the catabolic-inflammatory state of untreated HIV (“return-to-health”), which would predict more gain at lower baseline CD4 — consistent with the observed pattern; (2) loss of the appetite-suppressing or mitochondrial-toxicity effect of older agents (zidovudine, efavirenz, tenofovir disoproxil fumarate); and (3) a direct INSTI effect on adipocyte function. No single hypothesis explains the full pattern, and a combination is likely.

Why this matters: HIV cardiovascular risk

People with HIV carry roughly a two-fold elevated baseline risk of major cardiovascular events even after virologic suppression, driven by chronic immune activation and a higher prevalence of traditional risk factors. REPRIEVE (Grinspoon 2023 NEJM^[9]) randomized 7,769 adults with HIV and low-to-moderate ASCVD risk to pitavastatin 4 mg daily or placebo and reported a 35% relative reduction in major adverse cardiovascular events at median 5.1 years follow-up — a result strong enough that the DHHS HIV guidelines now recommend pitavastatin for most adults with HIV age ≥ 40. McCann 2021^[5] modeled the cardiovascular and diabetes consequences of 5–10 kg of INSTI-associated weight gain over 10 years and predicted meaningful excess MI, stroke, and incident type 2 diabetes. Reversing that weight gain is not cosmetic — it is cardiovascular prevention.

The GLP-1 evidence in people with HIV

Two recent cohort studies are the foundation. Nguyen 2024^[6] (Clinical Infectious Diseases) reported on 222 adults with HIV on stable suppressive ART who started a GLP-1 receptor agonist for obesity or type 2 diabetes. Mean weight loss at 12 months was 6.5% on semaglutide and 10.3% on tirzepatide, with no virologic breakthroughs and no excess adverse events compared with the published trial populations. Haidar 2024^[7] (AIDS, CNICS cohort) reported −6.1 kg mean weight loss at 12 months on semaglutide with stable CD4 and undetectable viral load throughout.

Zino 2023^[8] (HIV Medicine) is the narrative review most often cited by infectious-disease specialists. Key points: (1) no clinically significant pharmacokinetic interaction between any GLP-1 receptor agonist and any INSTI or boosted PI, (2) caution warranted with oral rilpivirine because rilpivirine absorption is pH-dependent and GLP-1 delayed gastric emptying may compound the absorption hit if the patient is also on a PPI, and (3) the SELECT trial cardiovascular benefit (Lincoff 2023^[10]) is likely additive on top of REPRIEVE pitavastatin benefit in people with HIV — an important consideration for the substantial subset with both HIV and obesity.

ART-GLP-1 interactions: the practical map

• INSTIs (dolutegravir, bictegravir, raltegravir, cabotegravir): No clinically meaningful interaction. INSTIs are UGT1A1 substrates with minor CYP3A4 metabolism; GLP-1 receptor agonists do not inhibit UGT or significantly affect CYP3A4. No dose adjustment required either direction.
• NRTIs (TAF, TDF, abacavir, lamivudine, emtricitabine): No interaction. NRTIs are renally cleared or non-CYP-metabolized.
• NNRTIs (efavirenz, doravirine): No significant interaction. Efavirenz is a CYP3A4 inducer but GLP-1 receptor agonists are not CYP3A4-metabolized.
• Rilpivirine (Edurant, in Odefsey, Juluca, Cabenuva oral lead-in): Caution. Rilpivirine requires an acidic stomach for absorption and is already compromised by PPIs. GLP-1 delayed gastric emptying may compound the absorption issue. If both are required, switch the patient to dolutegravir-based ART or use a non-rilpivirine regimen.
• Protease inhibitors (boosted darunavir, atazanavir): No direct interaction. Cobicistat and ritonavir are strong CYP3A4 inhibitors but GLP-1 receptor agonists are not CYP3A4 substrates.
• Long-acting injectable cabotegravir plus rilpivirine (Cabenuva): The intramuscular depot form bypasses the rilpivirine oral-absorption concern. No interaction with injectable GLP-1.

Magnitude: weight change at 12 months by ART context

HIV plus type 2 diabetes plus GLP-1

Type 2 diabetes is over-represented in people with HIV, partly from INSTI-associated weight gain and partly from baseline metabolic risk. Standard ADA glycemic-control algorithms apply: metformin first if not contraindicated, GLP-1 receptor agonist as the preferred add-on for patients with established ASCVD or high cardiovascular risk — which describes most patients with HIV after age 40. SELECT (Lincoff 2023^[10]) demonstrated a 20% relative reduction in MACE on semaglutide 2.4 mg in adults with established ASCVD and overweight or obesity without diabetes; the cardiovascular benefit is independent of weight loss and is plausibly additive with REPRIEVE pitavastatin in people with HIV.

Special considerations: lipodystrophy, pregnancy, and PMTCT

HIV-associated lipodystrophy. The older thymidine-analogue NRTIs (stavudine, zidovudine) caused a characteristic syndrome of peripheral lipoatrophy (facial, limb, buttock fat loss) plus central lipohypertrophy (visceral fat, buffalo hump). Modern ART regimens do not cause new lipoatrophy, but legacy patients carry it for life. GLP-1 receptor agonists reduce visceral and abdominal subcutaneous fat — helpful for the lipohypertrophy component — but do not reverse facial or limb lipoatrophy. Patients should be counseled that the central adiposity will improve while the peripheral wasting will not.

Pregnancy and prevention of mother-to-child transmission (PMTCT). GLP-1 receptor agonists are contraindicated in pregnancy. Patients planning conception should follow the standard 8-week washout protocol (see our GLP-1 pregnancy washout guide). ART should be continued at full dose throughout pregnancy and breastfeeding for PMTCT; do not pause ART. If pregnancy is unplanned and the patient is on a GLP-1, stop the GLP-1 immediately and continue ART.

The practical clinical protocol

1. Confirm viral suppression and current CD4. HIV viral load undetectable for ≥ 6 months and CD4 ≥ 200 cells/mm3 are the usual baseline. Lower CD4 is not a contraindication, but consult ID first.
2. Continue ART at full dose unchanged. Do not adjust the INSTI dose. If the patient is on oral rilpivirine, discuss switch to dolutegravir-based regimen before starting GLP-1.
3. Start GLP-1 with standard titration. Semaglutide 0.25 mg weekly escalating to 2.4 mg, or tirzepatide 2.5 mg weekly escalating to 10–15 mg. No HIV-specific dose adjustment.
4. Baseline labs: CMP, lipid panel, HbA1c, HIV viral load, CD4. Repeat lipid + HbA1c at week 12, 24, 52. HIV viral load and CD4 on the usual ID schedule (every 3–6 months).
5. Optional DEXA at baseline for patients with prior lipodystrophy or sarcopenic-obesity risk factors (see our lean-mass preservation protocol).
6. Coordinate with infectious-disease specialist. The obesity-medicine clinician and the ID clinician should share a problem list. Most ID specialists are now comfortable co-managing GLP-1 in PWH, but the formal handoff prevents medication-reconciliation errors.
7. Statin co-prescription. Per REPRIEVE (Grinspoon 2023^[9]) and DHHS guidelines, pitavastatin 4 mg daily is reasonable for most adults with HIV age ≥ 40 with low-to-moderate ASCVD risk regardless of LDL. See our GLP-1 plus statin interaction review.

Insurance and cost

ART is covered by all state Medicaid programs, the federal Ryan White HIV/AIDS Program, the AIDS Drug Assistance Program (ADAP) in every state, and commercial insurance with minimal cost-sharing. GLP-1 receptor agonist coverage for weight loss in HIV is unchanged from the general population: Medicare currently does not cover for weight loss alone but does cover for type 2 diabetes, established cardiovascular disease (post-SELECT label), or obstructive sleep apnea (post-Zepbound 2024 expansion). Medicaid coverage varies by state. Commercial coverage typically requires prior authorization with a documented BMI of 30, or 27 with a comorbidity — T2D, hypertension, dyslipidemia, OSA, or established ASCVD, all of which are over-represented in adults with HIV.

Provider routes: most patients will be co-managed by an infectious-disease specialist (for the ART) and either a primary-care clinician or an obesity-medicine specialist (for the GLP-1). A growing number of HIV clinics now offer in-house metabolic services and will prescribe the GLP-1 directly. The SELECT trial cardiovascular evidence is increasingly cited in HIV-clinic obesity protocols because it provides the strongest case for adding semaglutide on top of statin therapy.

Related research and tools

• GLP-1 plus statins interaction review — pitavastatin, rosuvastatin, atorvastatin co-prescription in HIV
• SELECT trial cardiovascular benefits — the MACE evidence that supports adding semaglutide in PWH with ASCVD risk
• GLP-1 pregnancy washout — 8-week discontinuation before conception while continuing ART for PMTCT
• GLP-1 lean-mass preservation protocol — protein, resistance training, and DEXA timing for older or lipodystrophic patients

Important disclaimer. This article is educational and does not constitute medical advice. Co-management of HIV plus obesity requires coordination between an infectious-disease specialist and an obesity-medicine or primary-care clinician; do not change any ART regimen without ID consultation. GLP-1 receptor agonists are contraindicated in pregnancy and in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Rilpivirine absorption is pH-dependent; combination with GLP-1 plus PPI requires individualized review. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if new prospective trial data on GLP-1 receptor agonists in people with HIV is published.